-
HyperPFU high-fidelity DNA polymerase Guide
2026-09-30
HyperPFU™ combines proofreading accuracy, processivity, and inhibitor tolerance for long, GC-rich, and sequence-sensitive PCR. This practical guide shows how to configure reactions for cloning, sequencing, and analytical validation workflows while avoiding common blunt-end and optimization pitfalls.
-
Cholesterol: From Membrane Assays to LNP CMC
2026-09-30
Cholesterol is the principal sterol linking membrane biophysics, lipid metabolism research, and lipid nanoparticle quality control. This guide develops an assay-to-CMC framework for selecting, handling, and interpreting cholesterol in membrane fluidity assays and mRNA-LNP studies.
-
DiI (DiIC18(3)) Membrane Labeling Guide
2026-09-29
DiI (DiIC18(3)) is a lipophilic orange fluorescent probe for visualizing plasma membrane distribution, lateral membrane movement, and membrane-associated cell behavior in live or fixed samples. It requires an organic solvent workflow and is not appropriate for water-only staining or selective labeling of intracellular organelles.
-
YAP–TEAD Links PPARα to Liver Growth and Regeneration
2026-09-29
The reference study identifies YAP–TEAD signaling as a mechanistic link between PPARα activation by WY-14643 (Pirinixic Acid) and liver enlargement or regeneration in mice. By combining pharmacologic treatment with hepatocyte-specific PPARα and YAP loss-of-function models, the work separates receptor-dependent effects from downstream tissue-growth responses and provides a framework for interpreting PPARα-driven hepatic remodeling.
-
Carfilzomib (PR-171) Research Workflows
2026-09-28
Build reproducible proteasome-inhibition assays around Carfilzomib (PR-171), from fresh DMSO stocks to orthogonal proteostasis and apoptosis readouts. The workflow also shows how to distinguish direct compound activity from schedule-dependent effects in combination and radiosensitization studies.
-
HyperPFU High-Fidelity DNA Polymerase for Reporters
2026-09-28
Build accurate PCR templates for fluorescence- or luciferase-based mRNA translation reporters, including constructs with long or GC-rich 5′-UTRs. HyperPFU™ combines proofreading fidelity with blunt-ended products, making it a strong fit for sequence-sensitive reporter construction—not a substitute for the in vitro transcription or cell-assay steps.
-
Phenothiazines Boost Macrophage Antibacterial Defense
2026-09-27
Qiu and colleagues report that phenothiazines strengthen macrophage antibacterial activity alongside increased reactive oxygen species (ROS), lysosomal activity, and autophagy; blocking ROS or autophagy weakened the effect. Their perphenazine results in a Salmonella Typhimurium infection model support further study of host-directed antibacterial strategies, while leaving compound-specific mechanisms and clinical relevance to be established.
-
Cell Senescence β-Galactosidase Staining Kit for HPV
2026-09-26
Connect HPV-16 E6 inhibitor studies to a practical, brightfield readout of treatment-associated senescence. This workflow uses the Cell Senescence β-Galactosidase Staining Kit alongside on-target and phenotype controls, while distinguishing senescence evidence from proof of drug efficacy.
-
SB202190 and the p38–ECM Trafficking Axis
2026-09-25
Explore how SB 202190, a p38 MAP kinase inhibitor, can help test the p38–extracellular-matrix trafficking axis in invasive cancer cells. This guide connects a high-content screening study to practical assay design while clarifying what pharmacological inhibition can—and cannot—show.
-
T7 RNA Polymerase: From Template to Antigen Breadth
2026-09-25
T7 RNA Polymerase enables promoter-directed RNA synthesis, but the intended RNA source matters as much as the enzyme when designing antigen-focused research. Learn how a dendritic-cell study using renal tumor RNA informs template design, assay controls, and the limits of translating in vitro transcription into immunotherapy research.
-
SIS3 Workflows for Smad3-Driven Research
2026-09-24
Use SIS3 to test whether a cellular response depends on Smad3 rather than treating TGF-β signaling as a single pathway output. This practical workflow connects selective pathway perturbation with fibrosis assays and the Smad3-linked mechanism reported in early-stage lung adenocarcinoma, while distinguishing target rationale from evidence for the compound itself.
-
ABT-737: BCL-2 Protein Inhibitor Workflows
2026-09-24
Use ABT-737 to test whether cancer cells depend on BCL-2, BCL-xL, or BCL-w for survival, with practical guidance for dose selection and apoptosis readouts. A recent study of tBID adds an important interpretation layer: mitochondrial death signaling can persist even when BAX and BAK are inactive, so target engagement and cell-death mechanism should be assessed separately.
-
TPPU: Soluble Epoxide Hydrolase Inhibitor Workflows
2026-09-23
Use TPPU to test how soluble epoxide hydrolase activity shapes fatty acid epoxide signaling, inflammatory responses, and osteoclast differentiation. This workflow connects potent human and mouse sEH inhibition with a recently reported liver–bone mechanism while clearly separating published findings from proposed experimental applications.
-
PFHxS Disrupts Lipid Homeostasis via PPARα
2026-09-23
This 2024 Environmental Science & Technology study integrates zebrafish lipidomics, transcriptomics, antagonist coexposure, and molecular simulation to show that environmentally relevant PFHxS exposure disrupts lipid homeostasis through PPARα-associated signaling. The work strengthens a mechanistic adverse-outcome framework while illustrating how receptor activation, downstream lipid remodeling, and toxicological interpretation can be evaluated together in vivo.
-
E-64 Workflow for Cysteine Protease Research
2026-09-22
E-64 is an irreversible L-trans-epoxysuccinyl peptide for mapping cysteine protease activity, cathepsin-dependent signaling, and lysosome-associated cell death. This practical workflow combines biochemical inhibition, active-site interpretation, and cell-based controls to distinguish protease activity from lysosomal membrane permeabilization.